GCC Protein Therapeutics Market

ID: MRFR/Pharma/50033-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026
GCC Protein Therapeutics Market Research Report By Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon), By Application (Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders) and By End User (Hospitals and Clinics, Specialty Centers) - Growth & Industry Forecast 2025 To 2035
GCC Protein Therapeutics Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.71%
2024 Market Size$ 12.24 Billion
2025 Market Size$ 12.94 Billion
2035 Market Size$ 22.55 Billion
Key Players
Amgen
Genentech
AbbVie
Bristol-Myers Squibb
Roche
Sanofi
Trends
  • Rising Demand for Biologics
  • Focus on Personalized Medicine
  • Collaborative Research Initiatives
Opportunities
  • Advancements in Biotechnology
  • Increasing Prevalence of Chronic Diseases
  • Regulatory Support for Biopharmaceuticals
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Type (USD Billion)
      1. 4.1.1 Monoclonal Antibodies
      2. 4.1.2 Recombinant Proteins
      3. 4.1.3 Hormones
      4. 4.1.4 Vaccines
    2. 4.2 Construction, BY Application (USD Billion)
      1. 4.2.1 Oncology
      2. 4.2.2 Autoimmune Diseases
      3. 4.2.3 Infectious Diseases
      4. 4.2.4 Metabolic Disorders
    3. 4.3 Construction, BY End Use (USD Billion)
      1. 4.3.1 Hospital
      2. 4.3.2 Research Laboratories
      3. 4.3.3 Pharmaceutical Companies
    4. 4.4 Construction, BY Mode of Administration (USD Billion)
      1. 4.4.1 Intravenous
      2. 4.4.2 Subcutaneous
      3. 4.4.3 Intramuscular
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Amgen (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Genentech (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AbbVie (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bristol-Myers Squibb (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Roche (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Sanofi (FR)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Novo Nordisk (DK)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eli Lilly (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Merck & Co. (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 GCC MARKET ANALYSIS BY TYPE
    3. 6.3 GCC MARKET ANALYSIS BY APPLICATION
    4. 6.4 GCC MARKET ANALYSIS BY END USE
    5. 6.5 GCC MARKET ANALYSIS BY MODE OF ADMINISTRATION
    6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CONSTRUCTION
    9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
    12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Billion)
    14. 6.14 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Billion)
    16. 6.16 CONSTRUCTION, BY END USE, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY END USE, 2024 TO 2035 (USD Billion)
    18. 6.18 CONSTRUCTION, BY MODE OF ADMINISTRATION, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY MODE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.2.4 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

GCC Protein Therapeutics Market Segmentation

GCC Protein Therapeutics Market By Type (USD Billion, 2025-2035)

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Hormones
  • Vaccines

GCC Protein Therapeutics Market By Application (USD Billion, 2025-2035)

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Metabolic Disorders

GCC Protein Therapeutics Market By End Use (USD Billion, 2025-2035)

  • Hospital
  • Research Laboratories
  • GCC Protein Therapeutics Market Companies

GCC Protein Therapeutics Market By Mode of Administration (USD Billion, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Intramuscular

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.